Abstract:TPS5597 Background: Immunotherapy has improved outcomes for patients with recurrent or metastatic cervical cancer whose tumors express PD-L1. Pembrolizumab (PEM), a monoclonal antibody that binds to programmed cell death 1 (PD 1) receptor, inhibits interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). It is approved for the treatment of recurrent or metastatic cervical cancer. Despite promising results, new strategies are being developed to improve immunotherapy responses. This includes DNA-damaging agents that have the potential to enhance the response to immunotherapy by promoting neo-antigen release, increasing tumor mutational burden, and enhancing PD-L1 expression. Poly-ADP-ribose polymerase (PARP) inhibitors, such as olaparib, have shown synergy with immunotherapy in preclinical and early clinical studies. PARP-based therapy is based on the inhibition of single-strand DNA repair, leading to DNA damage and increased tumor mutational burden. As a result, the tumor becomes a more attractive target for immunotherapy. Based on this, we are investigating the interplay between homologous recombination (HR) repair deficiency, another mechanism of DNA repair, and solid tumor response to ICI. Our approach uses an all-inclusive functional immunofluorescence assay of the Fanconi Anemia triple-staining immunofluorescence (FATSI) we developed and can be performed in paraffin-embedded tumors. Methods: This is a phase II open-label single center trial evaluating the role of PEM and olaparib in patients with metastatic cervical cancer who have progressed on first-line standard of care chemotherapy. FATSI will be performed in all patients. We hypothesize that FATSI negative tumors will be associated with improved responses. Other eligibility criteria include measurable disease by imaging, 18 years of age or older, and no previous exposure to ICI or PARP inhibitor. The primary objective is to evaluate the immune-related objective response rate (iORR) achieved in patients with FA Repair Pathway functionally competent and functionally deficient tumors. Secondary objectives include 20-week progression free survival and overall survival. Other exploratory objectives include evaluation of the mutation load and markers of neo-antigenicity, T cell receptor clonotype analyses (before and after treatment), and alterations in HR repair genes. We will utilize a two-stage phase II design to detect an iORR ≥ 20% in the whole population tested vs. the null hypothesis that the true iORR ≤5%, represents a response by chance alone or other infrequent unknown mechanisms. An interim analysis requires at least 2 of the first 20 evaluable patients enrolled have an objective response. If this occurs, we will accrue 28 additional patients to total 48. Enrollment is ongoing and two patients are currently on treatment. Clinical trial information: NCT04483544.

Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial

A Phase II Trial of Cytoreductive Surgery Combined with Niraparib Maintenance in Platinum-Sensitive, Secondary Recurrent Ovarian Cancer: SGOG SOC-3 Study

Pamiparib in Patients with Locally Advanced or Metastatic HER2-negative Breast Cancer with Germline BRCA Mutations: a Phase II Study

377O A Randomized Double-Blind Phase III Study of Niraparib Versus Placebo As Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

Tolerability, Safety, and Preliminary Antitumor Activity of Fuzuloparib in Combination with SHR-1316 in Patients with Relapsed Small Cell Lung Cancer: a Multicenter, Open-Label, Two-Stage, Phase Ib Trial.

First-line Sintilimab Combined with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer: A Phase II Study and Post-Hoc Biomarker Analysis.

PARALLEL 303: Phase 2 Randomized Study of Pamiparib Vs Placebo As Maintenance Therapy in Patients (pts) with Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-Based First-Line (1L) Chemotherapy.

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

P1.12-04 A Ph3 Study of Niraparib As Maintenance Therapy in 1L Platinum Responsive Extensive Disease Small Cell Lung Cancer Patients

Poly ADP-ribose polymerase inhibitor promotes the immunoradiotherapeutical efficacy in small cell lung cancer.

Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study)

PARP Inhibitor Plus Radiotherapy Reshapes an Inflamed Tumor Microenvironment That Sensitizes Small Cell Lung Cancer to the Anti-Pd-1 Immunotherapy.

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.

998TiPPamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China

CTNI-44. A PHASE 0 ‘TRIGGER’ TRIAL OF PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA PATIENTS

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer

Phase I/II Investigator-Initiated Study of Olaparib and Temozolomide in SCLC: Final Analysis and CNS Outcomes

Pamiparib Monotherapy for Patients with Germline BRCA1/2 -Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study